Arrowhead Pharmaceuticals develops RNAi-based medicines that silence disease-causing genes using its proprietary TRiM platform. The company has 18 drug candidates in clinical trials (Phase 1 through Phase 3) and achieved its first FDA-approved product, REDEMPLO (plozasiran), in 2025 for Familial Chylomicronemia Syndrome. Arrowhead has licensed multiple programs to partners including Amgen, Takeda, GSK, and Novartis, while retaining commercialization rights for key pipeline assets.
Q2 FY2026 — expected 2026-09-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-25 | 2025-09-30 | 0000879407-25-000029 | EDGAR | 84K words |
| 2024-11-26 | 2024-09-30 | 0001628280-24-049277 | EDGAR | 78K words |
| 2023-11-29 | 2023-09-30 | 0001628280-23-040219 | EDGAR | 76K words |
| 2022-11-28 | 2022-09-30 | 0001628280-22-030869 | EDGAR | 72K words |
| 2021-11-22 | 2021-09-30 | 0001564590-21-057888 | EDGAR | — |
| 2020-11-23 | 2020-09-30 | 0001564590-20-054893 | EDGAR | — |
| 2019-11-25 | 2019-09-30 | 0001564590-19-044376 | EDGAR | — |
| 2018-12-11 | 2018-09-30 | 0001564590-18-030805 | EDGAR | — |
| 2017-12-12 | 2017-09-30 | 0001564590-17-024834 | EDGAR | — |
| 2016-12-14 | 2016-09-30 | 0001564590-16-030217 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0000879407-26-000057 | EDGAR | 28K words |
| 2026-02-05 | 2025-12-31 | 0000879407-26-000034 | EDGAR | 90K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038858 | EDGAR | 22K words |
| 2025-05-12 | 2025-03-31 | 0001628280-25-024666 | EDGAR | 21K words |
| 2025-02-10 | 2024-12-31 | 0001628280-25-004634 | EDGAR | 64K words |
| 2024-08-08 | 2024-06-30 | 0001628280-24-036104 | EDGAR | 18K words |
| 2024-05-09 | 2024-03-31 | 0001628280-24-022215 | EDGAR | 17K words |
| 2024-02-06 | 2023-12-31 | 0001628280-24-003492 | EDGAR | 15K words |
| 2023-08-07 | 2023-06-30 | 0001628280-23-027771 | EDGAR | 24K words |
| 2023-05-02 | 2023-03-31 | 0001628280-23-014856 | EDGAR | 22K words |
| 2023-02-06 | 2022-12-31 | 0001628280-23-002413 | EDGAR | 18K words |
| 2022-08-04 | 2022-06-30 | 0001628280-22-021068 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0000879407-26-000058 | EDGAR | 2K words |
| 2026-03-20 | 0000879407-26-000037 | EDGAR | 1K words |
| 2026-02-05 | 0000879407-26-000033 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-010582 | EDGAR | 48K words |
| 2026-01-09 | 0001193125-26-007971 | EDGAR | 2K words |
| 2026-01-06 | 0000879407-26-000004 | EDGAR | 2K words |
| 2025-11-25 | 0000879407-25-000027 | EDGAR | 2K words |
| 2025-11-18 | 0000879407-25-000019 | EDGAR | 2K words |
| 2025-09-12 | 0000879407-25-000010 | EDGAR | 49K words |
| 2025-09-11 | 0000879407-25-000007 | EDGAR | 1K words |
299 total filings indexed. 267 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000879407 |
| Ticker | ARWR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.arrowheadpharma.com |
| Listed | 1995-02-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ARWR (~200 tokens, structured JSON with cryptographic provenance)